ClinicalTrials.gg
CompletedNCT06879067Updated Mar 17, 2025

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

A Phase 1 interventional study of Placebo and Foralumab Nasal in Safety and Tolerability, sponsored by Tiziana Life Sciences LTD. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Tiziana Life Sciences LTD · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2019, 7 years 3 months ago, and no results have been posted to the registry.
  • Registered 6 years 3 months after the study started (first participant enrolled Nov 2018, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal is to establish the safety of administration of nasal foralumab to healthy volunteers in escalating doses to determine the dose at which immune effects are observed. Patients will receive doses for 5 consecutive days and have a follow-up period.

Read the detailed description

This was a randomized, double blind phase 1 dose escalation study evaluating 3 dose levels of foralumab via intranasal administration from single-dose vials. The rationale behind the proposed research was to establish an immunologically active dose of foralumab given by the nasal route. Given that foralumab has never been administered by the nasal route to humans, this was a safety and dose finding study. Each dose group was observed until Day 7 to assess safety before moving to the next higher dose. This study also helped determine the dose at which immune effects (induction of regulatory T cells and changes in cytokine profiles of immune cells) were observed in subjects treated with foralumab.

02

Conditions studied

  • Safety
  • Tolerability

Keywords

  • foralumab
  • safety
  • tolerability
  • phase 1
03

In context

Lead sponsor

Tiziana Life Sciences LTD is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ages 18 to 65 years
  • Healthy adults
  • Ability and willingness to provide and comply with study requirements and procedures

Exclusion criteria

Exclusion Criteria:

  • Chronic medical disease compromising organ function
  • within the past month
  • Pregnancy or lactating
  • Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, asthma, thyroid disease, or type I diabetes
  • Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within the past year.
  • Participation in another clinical trial within the past 30 days
  • Known history of drug or ETOH abuse
  • Screening labs outside of the normal range; EBV IgM positive subjects with clinical signs will not receive study drug
  • Nasal corticosteroids; antihistamines; nasal flu dosing within 30 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    nasal foralumab 10 μg daily

    Group A: nasal foralumab 10 μg daily for 5 days

    Drug: Foralumab Nasal

  • Experimental
    nasal foralumab 50 μg daily

    Group B: nasal foralumab 50 μg daily for 5 days

    Drug: Foralumab Nasal

  • Experimental
    nasal foralumab 250 μg daily

    Group C: nasal foralumab 250 μg daily for 5 days

    Drug: Foralumab Nasal

  • Placebo comparator
    placebo

    The placebo was acetate buffer. It was handled in a manner identical to active drug.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo nasal spray

  • DrugForalumab Nasal

    foralumab nasal spray

06

What researchers measure

Primary outcomes

  1. Safety- Adverse Events

    Establish the safety of administration of nasal Foralumab to healthy volunteers in escalating doses for 5 consecutive days. Two or more serious adverse events occur that are possibly, probably or definitely related to nasal Foralumab.

    Time frame: Day 1 vs End of Study (Day 30)

  2. Immune Effect

    Determine the dose at which immune effects are observed in subjects treated with Foralumab

    Time frame: Dat 1 vs End of Study (Day 30)

07

Study locations

1 site
  • Ann Romney Center for Neurologic Diseases
    Boston, Massachusetts 02115, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jul 2019, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 17, 2025
StartActual
Nov 12, 2018
Primary completionActual
Jul 23, 2019
CompletionActual
Nov 9, 2020
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06879067
Lead sponsor
Tiziana Life Sciences LTD
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Nov 12, 2018
Primary completion
Jul 23, 2019
Completion
Nov 9, 2020
Last update
Mar 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion